multi pics
Volume 4, Issue 3
In this Issue...

> Introduction to This Issue of The Bridge
> The Buprenorphine Treatment Scene: An Interview with Dr. Jeffrey Junig
> Access to Buprenorphine Treatment: Complexities Accross the National Landscape
> Regarding Substance Using Patients and Buprenorphine: A Primary Healthcare Challenge
> Experience and Opinions are Valuable, But We Need Data
> The Necessity of Counseling in Buprenorphine Treatment

> A Business Case for Including Medication in Treatment Plans
> Some Challenges to Dr. Junig's Assertions
> Right on, Dr. Junig!
>Counseling without Training?

> Some Missing Points in Dr. Junig's Interview

Download a PDF of this entire issue

Blueline

> Introduction to this issue of The Bridge: Buprenorphine and Integration
By Paul Roman, PhD
University of Georgia
Editor, The Bridge

The last two issues of The Bridge have explored integration of the treatment of substance use disorders (SUD) into mainstream medical practice. In this issue, we take a look at medication-assisted treatment—specifically, buprenorphine treatment, as one example of integration.
Read More...

Blueline

>The Buprenorphine Treatment Scene:
An Interview with Dr. Jeffrey Junig

Dr. Jeffrey Junig, a psychiatrist in private practice in
Fond du Lac, WI, has written widely in popular media and specialized blogs about addiction medicine and the use of buprenorphine.
Read More...

Blueline

> Access to Buprenorphine Treatment: Complexities across the National Landscape
Hannah Knudsen, PhD
University of Kentucky

I read with great interest the interview between Dr. Paul Roman from the University of Georgia and Dr. Jeffrey Junig. As I read the transcript, there were many points of intersection with research that our team at the
University of Kentucky is conducting on the impact of the Affordable Care Act on buprenorphine treatment...Read More...

Blueline

>Regarding Substance Using Patients and Buprenorphine: A Primary Healthcare Challenge
Steve Martino, PhD
Ismene Petrakis, M.D.
Yale University School of Medicine
Dr. Junig presents a frank assessment of the multiple regulatory and political factors that have impeded greater utilization of buprenorphine for the treatment of opiate addiction. Read More...

Blueline

>Experience and Opinions are Valuable,
but We Need Data

Mike Boyle, MA
University of Wisconsin

I usually cringe when I hear the phrase “based on my experience,” as it is likely that an opinion is forthcoming without supporting data. Still, I wish to share some experiences that led me to support many of Dr. Junig’s points, "based on my mistakes” as a former administrator of a substance use treatment organization. Read More...

Blueline

> The Necessity of Counseling in Buprenorphine Treatment
Louise Haynes, MSW
Medical University of South Carolina

In conservative areas of the country, like South Carolina where I live, buprenorphine has been increasingly accepted as a legitimate, life-saving treatment. Read More...

Blueline

>A Business Case for Including Medication in Treatment Plans
Dennis McCarty, PhD
Oregon Health & Science University
Using medication for the treatment of alcohol and opioid use disorders is good for business and practice.
Read More...


>Some Challenges to Dr. Jung's Assertions
Ron Jackson, MSW
University of Washington School of Social Work
First a question to The Bridge editor: Why are you interviewing a psychiatrist about the use of buprenorphine in primary care physicians? Why not interview a primary care physician about...Read More...


>Right on, Dr. Junig!
Holly Hagle, PhD
IRETA/National SBIRT ATTC
Dr. Junig captures the emotion that was swirling around the addiction field in the year 2000 when the DATA legislation was passed. It did feel revolutionary. Read More...


>Counseling without Training?
Elizabeth Wells, PhD
University of Washington School of Social Work
Dr. Junig advocates for wider availability of buprenorphine/Suboxone for both opioid dependence treatment and reduction of harm from opioid overdose. His comments in this regard are right on, even though they most certainly will raise the hackles of those in (and outside) the recovery field...Read More...


>Some Missing Points in Dr. Junig's Interview
Dennis Daley, PhD
University of Pittsburgh
In responding to Dr. Junig's comments, I got input from several highly-experienced clinicians and physicians, psychiatrists and internal medicine specialists, who have large practices involving buprenophrine. Read More...

Blueline

Download a PDF of this entire issue


The Bridge is a semi-annual e-pub that links science and service by providing information and tools on technology transfer and implementation science strategies.


Blueline

Coming up soon:

An ATTC Issue Brief: Advancing the Integration of Substance Use Disorder Services and Health Care

The Bridge Video Talk Show for this issue: Watch your email for details!

Blueline

Related Posts from the ATTC/NIATx Service Improvement Blog:

Integration: The Great Debate

What happens if they say "Yes"?


Inspiring Change Through SBIRT: Start with the "Why"

Blueline

Are you interested in contributing to the next issue of The Bridge?
Contact Paul Roman, Editor of The Bridge, or send an email to thebridge@attcnetwork.org.

We want to hear from you!
Email your thoughts about this issue of The Bridge to Maureen Fitzgerald at the ATTC Network Coordinating Office.

The Bridge Editorial Board

Subscribe to The Bridge

Connect with us to join the conversation online!

Find us on Facebook Follow us on Twitter Join us on LinkedIn Watch us on YouTube